GSTT2B

Across TCGA pan-cancer cohorts, GSTT2B mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of GSTT2B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where GSTT2B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types GSTT2B is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

CCRCC, LSCC, and LUAD are the cancer types where GSTT2B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GSTT2B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	All	−0.481	.011	6	view →
LSCC	All	All	−0.859	<.001	4	view →
LUAD	All	All	−0.563	.002	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

GSTT2B–CCRCC

Open the CCRCC breakdown →